BMX.WAR Biomaxima

Healthcare Biotechnology Warsaw Stock Exchange
9.50 PLN
Close of Oct 29, 2026
9.30 13.25
Market cap
PLN 39.8M
P/E
45.2x
P/B
0.83x
ROE
2.9%
Dividend yield
-
Fundamental score
1.6/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is BMX.WAR undervalued?

Graham number
Price9.50
Graham value7.36
Premium29.1%

BMX.WAR trades 29.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biomaxima fundamental analysis

7 of 22 checks passed

ROE 0/2

Low return on equity (2.9%), below 10%.

ROA 1/1

Return on assets (1.7%) is above the industry median (-18.6%).

Profit Consistency 2/2

Profitable for 6 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Last year's EPS growth (-80.4%) is not above the 5-year average (-57.7% a year).

Earnings Growth vs Industry 0/1

Last year's EPS growth (-80.4%) is below the industry median (2.6%).

Revenue Growth 0/2

Revenue shrank 24.9% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (34.5%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 0/1

EBIT is negative, against interest expense, below 5x.

PE vs Market 0/1

PE (46.2x) is above the market median (11.6x).

PE vs Industry 0/1

PE (46.2x) is above the industry median (18.6x).

PBV 1/1

Price to book (0.8x) is below the industry median (3.6x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 39.1, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Biomaxima stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biomaxima

BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which include real time PCR, nucleic acid isolation, NA and PCR electrophoresis, protein electrophoresis, enzymes, antibio…

Full company profile